SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew R. Sicotte who wrote ()5/3/1997 10:07:00 PM
From: DZOO   of 834
 
To all: This may be a dumb question but it is one I am compelled to ask. TXB is developing NOVASTAN as an adjunctive therapy to thrombolytics such as t-PA and streptokinase. What about Retavase? Streptokinase and t-PA are delivered via continuous infusion. Retavase can be given in a simple two-shot form. My sources indicate that Retavase is now the thrombolytic of choice. Can NOVASTAN be used with Retavase without additional clinical trials? Is TXB using Retavase in their clinicals? I hope I'm just being paranoid and this is a "non-problem."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News